RFK Jr. continues to serve as HHS Secretary with no public signals of imminent departure, actively testifying before Senate and House committees on the fiscal 2027 budget and defending administration policies on vaccines, staffing, and chronic disease prevention. Recent internal shifts, including the resignation of his chief spokesperson over flavored vape approvals and the FDA commissioner’s exit, reflect ongoing agency turbulence but have not disrupted Kennedy’s role or prompted any White House moves against him. He has addressed emerging health issues such as the hantavirus outbreak alongside President Trump while advancing plans to rebuild HHS staff levels after prior reductions. With these developments showing sustained engagement through mid-May and no overriding political pressure or structural barriers evident, trader consensus places a 71 percent probability on him remaining in office through year-end.